0.401

5.50% 0.0209

After Hours: .42 0.019 +4.74%

Soligenix Inc (SNGX)

Overview News Price History Financials Discussions Forecast Stock Split

Soligenix Inc stock is traded at $0.401, with a volume of 978.76K. It is up +5.50% in the last 24 hours and up +10.13% over the past month. Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Previous Close:

$0.3801

Open:

$0.380001

24h Volume:

978.76K

Relative Volume:

0.17

Market Cap:

$8.73M

Revenue:

$200.00K

Net Income/Loss:

$-10.95M

P/E Ratio:

-0.2032

EPS:

-1.9738

Net Cash Flow:

$-10.78M

1W Performance:

+0.25%

1M Performance:

+10.13%

6M Performance:

-63.55%

1Y Performance:

-88.07%

1-Day Range:

$0.38

$0.4219

1-Week Range:

$0.38

$0.4219

52-Week Range:

$0.28

$3.44

Soligenix Inc Stock (SNGX) Company Profile

Name

Soligenix Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

609-538-8200

Address

29 EMMONS DRIVE, PRINCETON

Employee

Twitter

@Soligenix_Inc

Next Earnings Date

2026-08-13

Latest SEC Filings

SNGX's Discussions on Twitter

Compare SNGX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNGX Soligenix Inc	0.401	8.27M	200.00K	-10.95M	-10.78M	-1.9738
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Soligenix Inc Stock (SNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-14-17	Reiterated	Maxim Group	Buy
Jul-17-17	Initiated	H.C. Wainwright	Buy

Soligenix Inc Stock (SNGX) Latest News

Aug 20, 2026

Soligenix (SNGX) Earnings Reading: The EPS Result Is Above Expectation in the Latest Session; Share Move - dars.gov.et

Aug 20, 2026

Aug 19, 2026

Soligenix (SNGX) Financial Results: The EPS Result Is Above Expectation in the Latest Reading; Latest Reaction: Shares Finish 3.79% Lower in the Available RecordRevenue Beat Analysis - vinanet.vn

Aug 19, 2026

Aug 17, 2026

SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Marginal BeatAnalyst Coverage Count - vinanet.vn

Aug 17, 2026

Aug 14, 2026

Soligenix Stock Price Forecast. Should You Buy SNGX? - StockInvest.us

Aug 14, 2026

Aug 13, 2026

SNGX Q1 2026 Earnings: Narrower Loss Offers Slight Beat, Yet No Revenue and Stock DipEarnings Trend Analysis - Vinanet

Aug 13, 2026

Aug 12, 2026

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine - Smartkarma

Aug 12, 2026

Aug 11, 2026

Soligenix to Present at BIO Investment & Growth Summit (PR Newswire) - Aktiellt

Aug 11, 2026

SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Share ReactionMid-Term Outlook - vinanet.vn

Aug 11, 2026

Aug 10, 2026

Soligenix culls topical lymphoma asset after Phase III miss - Yahoo Finance

Aug 10, 2026

Aug 08, 2026

Soligenix (SNGX) Receives a Buy from Alliance Global Partners - The Globe and Mail

Aug 08, 2026

Aug 07, 2026

A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo

Aug 07, 2026

Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026

Soligenix Q2 net loss narrows as R&D expenses fall - TradingView

Aug 07, 2026

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results - Barchart.com

Aug 07, 2026

SNGX Q1 2026 Earnings: Narrower Loss Provides Modest Upside SurpriseEarnings Beat Streak - vinanet.vn

Aug 07, 2026

Aug 06, 2026